By September 15, 2026: Billing team must update claims processing system to add the 19 new HCPCS codes (J2351, J2781, J3263, J9024, J9272, J9275, J9277, J9289, J9298, J9329, J9345, J9999, Q5156, Q5159, Q5161, Q5164, Q5165, Q5166, Q5167, Q5171) with new maximum dosage and frequency limits per UnitedHealthcare's updated policy. Remove HCPCS code C9151 from billing rules. Update dosage limits in system for: Beovu, Byooviz, Cimerli, Eylea, Eylea HD, Lucentis, Pavblu, Susvimo, Syfovre, and Vabysmo. Configure system to treat biosimilars (e.g., Aukelso, Boncresa, Bosaya, Enoby, Jubereq, Ospomyv, Osvyrti, Oziltus, Xbryk, Xtrenbo) as therapeutically equivalent to reference biologics for maximum dosage application. Billing team and coding staff must verify new drug names and NDC mappings in system. Notify providers of maximum allowed quantities by HCPCS units. Claims submitted on or after October 1, 2026 with dosages exceeding new limits will be denied unless supporting medical necessity documentation is provided.